CD274 and neoplasm: Despite a clear clinical benefit and the statistical significance across all the subgroups both in terms of PFS and OS shown in the KEYNOTE826 study, pembrolizumab in combination with the standard of care first-line treatment (platinum-based chemotherapy ± bevacizumab) granted the regulatory agency approvals by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) exclusively for patients with a significant tumor expression of PD-L1, defined as CPS ≥ 1, thus warranting further investigation.